{"id":"empagliflozin-jardiance","safety":{"commonSideEffects":[{"rate":"8–13","effect":"Genital mycotic infections"},{"rate":"4–8","effect":"Urinary tract infections"},{"rate":"3–5","effect":"Polyuria"},{"rate":"<1","effect":"Diabetic ketoacidosis"},{"rate":"2–4","effect":"Volume depletion / hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SGLT2 is responsible for reabsorbing filtered glucose in the proximal tubule of the nephron. By blocking this transporter, empagliflozin allows glucose to be excreted in the urine, thereby lowering blood glucose levels independently of insulin secretion. This mechanism also promotes modest osmotic diuresis and has cardiovascular and renal protective effects beyond glycemic control.","oneSentence":"Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:29:08.648Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Chronic kidney disease"}]},"trialDetails":[{"nctId":"NCT05262764","phase":"","title":"Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-04-15","conditions":"Heart Failure","enrollment":1200},{"nctId":"NCT06527846","phase":"","title":"Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-10-22","conditions":"Kidney Disease, Chronic","enrollment":1024},{"nctId":"NCT07107945","phase":"PHASE3","title":"A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-12-09","conditions":"Chronic Kidney Disease","enrollment":120},{"nctId":"NCT07479108","phase":"NA","title":"Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions","status":"COMPLETED","sponsor":"ADIUM","startDate":"2024-11-29","conditions":"Bioequivalance","enrollment":32},{"nctId":"NCT06055452","phase":"PHASE4","title":"Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2024-01-19","conditions":"Pre-Heart Failure, Hypertension","enrollment":120},{"nctId":"NCT05174507","phase":"PHASE2","title":"Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes","status":"WITHDRAWN","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-06-24","conditions":"Postprandial Hypoglycemia","enrollment":""},{"nctId":"NCT06094920","phase":"PHASE4","title":"Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2024-07-29","conditions":"Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Type 2, Diabetes Mellitus","enrollment":12},{"nctId":"NCT06287073","phase":"","title":"JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2024-03-29","conditions":"Kidney Disease, Chronic","enrollment":299},{"nctId":"NCT07372118","phase":"PHASE1","title":"Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in Fast Condition","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2025-09-27","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":32},{"nctId":"NCT07365358","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2026-03","conditions":"Diabete Type 2","enrollment":200},{"nctId":"NCT07055282","phase":"EARLY_PHASE1","title":"SGLT2i in Kidney Stones","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-11-20","conditions":"Kidney Stones","enrollment":32},{"nctId":"NCT07325435","phase":"PHASE4","title":"Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists","status":"ACTIVE_NOT_RECRUITING","sponsor":"MaryAnn Banerji","startDate":"2024-12-21","conditions":"Type 2 Diabetes (T2DM)","enrollment":60},{"nctId":"NCT07266766","phase":"PHASE1","title":"Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2025-08-05","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":40},{"nctId":"NCT04447911","phase":"PHASE4","title":"Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-02-04","conditions":"Hyponatremia, SIADH, Liver Failure","enrollment":172},{"nctId":"NCT05081219","phase":"PHASE2","title":"SNIFF - Combo INI+EMPA Trial","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2021-09-14","conditions":"Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease","enrollment":47},{"nctId":"NCT07213895","phase":"PHASE1","title":"Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2025-05-21","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":14},{"nctId":"NCT05130463","phase":"","title":"Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-03-22","conditions":"Diabetes Mellitus, Type 2","enrollment":1053},{"nctId":"NCT05350202","phase":"","title":"Emp-Activity: Empagliflozin Functional Capacity","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-12-18","conditions":"Heart Failure","enrollment":3431},{"nctId":"NCT07035457","phase":"PHASE1","title":"A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2025-07-02","conditions":"Healthy","enrollment":15},{"nctId":"NCT05614115","phase":"PHASE1","title":"Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD","status":"COMPLETED","sponsor":"University of Utah","startDate":"2023-03-21","conditions":"End-stage Kidney Disease, Kidney Disease, Chronic, Dialysis","enrollment":62},{"nctId":"NCT05236673","phase":"","title":"Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-07-28","conditions":"Heart Failure","enrollment":610},{"nctId":"NCT06766500","phase":"PHASE1","title":"Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/850 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy® 5 mg/850 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)","status":"COMPLETED","sponsor":"Gedeon Richter Plc.","startDate":"2025-01-20","conditions":"Diabetes Mellitus Type 2","enrollment":64},{"nctId":"NCT06792968","phase":"PHASE1","title":"Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)","status":"COMPLETED","sponsor":"Gedeon Richter Plc.","startDate":"2025-03-30","conditions":"Diabetes Mellitus Type 2","enrollment":64},{"nctId":"NCT06894784","phase":"PHASE3","title":"A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2025-04","conditions":"Diabetes Type 1","enrollment":36},{"nctId":"NCT03790787","phase":"PHASE1","title":"Drug Interaction Study Between Dorzagliatin and Empagliflozin","status":"COMPLETED","sponsor":"Hua Medicine Limited","startDate":"2019-04-18","conditions":"Patients","enrollment":16},{"nctId":"NCT06249932","phase":"PHASE4","title":"Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-03-13","conditions":"Heart Failure with Reduced Ejection Fraction, End Stage Renal Disease on Dialysis","enrollment":95},{"nctId":"NCT05036317","phase":"PHASE3","title":"Empagliflozin for the Treatment of Postprandial Hypoglycemia","status":"TERMINATED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-03-11","conditions":"Postprandial Hypoglycemia","enrollment":40},{"nctId":"NCT06450262","phase":"PHASE1","title":"Bioequivalence Study to Compare Empagliflozin/ Metformin HCl 12.5mg/1000mg Film-coated Tablets","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2024-01-04","conditions":"Type2diabetes","enrollment":36},{"nctId":"NCT03437330","phase":"PHASE4","title":"Empagliflozin Effect on Glucose Toxicity","status":"WITHDRAWN","sponsor":"University Hospital Tuebingen","startDate":"2021-10-27","conditions":"Type2 Diabetes Mellitus","enrollment":""},{"nctId":"NCT05162014","phase":"","title":"To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-12-20","conditions":"Diabetes Mellitus, Type 2","enrollment":494679},{"nctId":"NCT06337409","phase":"PHASE1","title":"Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai Volunteers","status":"NOT_YET_RECRUITING","sponsor":"International Bio service","startDate":"2024-07-01","conditions":"Healthy Volunteer","enrollment":30},{"nctId":"NCT06308679","phase":"PHASE1","title":"A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions","status":"NOT_YET_RECRUITING","sponsor":"Pharma Nueva","startDate":"2024-05-28","conditions":"Healthy Vollunteer","enrollment":28},{"nctId":"NCT02367131","phase":"","title":"Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2015-02-24","conditions":"Diabetes Mellitus, Type 2","enrollment":419},{"nctId":"NCT03807440","phase":"","title":"DIA_CENTRAL:T2D Treatment Pattern in Central Europe","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-08-26","conditions":"Diabetes Mellitus, Type 2","enrollment":4083},{"nctId":"NCT06103279","phase":"PHASE2, PHASE3","title":"Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2023-11","conditions":"Cancer","enrollment":40},{"nctId":"NCT05083949","phase":"PHASE1","title":"A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-07-23","conditions":"Healthy","enrollment":32},{"nctId":"NCT05956522","phase":"PHASE1","title":"Bioequivalence Study of Empagliflozin And Linagliptin Tablets in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2022-07-01","conditions":"Healthy","enrollment":106},{"nctId":"NCT03462069","phase":"PHASE2","title":"Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-12","conditions":"Diabetes Mellitus","enrollment":41},{"nctId":"NCT02489942","phase":"","title":"Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2015-06-12","conditions":"Diabetes Mellitus, Type 2","enrollment":8145},{"nctId":"NCT04431141","phase":"PHASE1","title":"Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2020-09-15","conditions":"Type 2 Diabetes Mellitus","enrollment":32},{"nctId":"NCT04049045","phase":"PHASE2","title":"Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure","status":"COMPLETED","sponsor":"Christian Schulze","startDate":"2019-09-29","conditions":"Acute Decompensated Heart Failure","enrollment":60},{"nctId":"NCT03642717","phase":"","title":"Regulatory Request NIS in Korea","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-08-21","conditions":"Diabetes Mellitus, Type 2","enrollment":658},{"nctId":"NCT02848833","phase":"","title":"JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-08-10","conditions":"Diabetes Mellitus, Type 2","enrollment":3368},{"nctId":"NCT04013581","phase":"PHASE4","title":"Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2019-08-05","conditions":"Type 2 Diabetes Mellitus","enrollment":121},{"nctId":"NCT03259490","phase":"PHASE1","title":"This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-08-31","conditions":"Healthy","enrollment":30},{"nctId":"NCT03629054","phase":"PHASE1","title":"This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-08-27","conditions":"Healthy","enrollment":30},{"nctId":"NCT04043702","phase":"","title":"Combination of Topiramate and Empagliflozin is Considered a Good Option for the Treatment of Obesity","status":"COMPLETED","sponsor":"Ministry of Health and Population, Egypt","startDate":"2019-01-04","conditions":"Obesity","enrollment":200},{"nctId":"NCT03771781","phase":"NA","title":"Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2018-04-16","conditions":"Type 2 Diabetes","enrollment":48},{"nctId":"NCT02729766","phase":"PHASE2, PHASE3","title":"Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2016-03","conditions":"Inappropriate ADH Syndrome","enrollment":15},{"nctId":"NCT02284269","phase":"","title":"Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Pharmaceuticals and Medical Devices Agency, Japan","startDate":"2014-10","conditions":"Diabetes Mellitus, Type 2","enrollment":18000},{"nctId":"NCT01844531","phase":"PHASE1","title":"Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-04","conditions":"Healthy","enrollment":24},{"nctId":"NCT01001962","phase":"PHASE4","title":"Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics","status":"UNKNOWN","sponsor":"Aristotle University Of Thessaloniki","startDate":"2016-01","conditions":"Hypertension, Type II Diabetes","enrollment":1054}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Empagliflozin (Jardiance®)","genericName":"Empagliflozin (Jardiance®)","companyName":"University Hospital Tuebingen","companyId":"university-hospital-tuebingen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion. Used for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}